PCV4: THE ECONOMIC IMPACT OF HYPERTENSION STUDY FROM THE PISTOIA PROJECT  by Potenza, A et al.
Abstracts 25
Subjective well-being (v. Zerssen scale) improved during
RT from 15.7  8 to 11.8  8 (p  0.001).
CONCLUSION: Alterable cardiovascular risk factors
and subjective quality of life are significantly improved
by health training and treatment during standardized car-
diac inpatient rehabilitation therapy. Follow-up studies
are needed to assess the long-term course and to improve
preventive strategies.
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OBJECTIVE: Within the Pistoia Project (PP), a large
screening study whose objective is the identification of
hypertensive disease, organ damage, and related risk fac-
tors to activate actions of primary and secondary preven-
tion, we conducted a preliminary cost of illness analysis
to investigate if age, gender, and/or severity of hyperten-
sion could influence the use of healthcare services and
therefore have a direct impact on costs.
METHODS: Forty-five patients’ records were randomly
selected from the GP’s screening forms of the PP: patients
were either hypertensive or normotensive under treat-
ment. Using healthcare codes, we computed hospital data
(DRG code and cost), while pharmaceutical consumption
(units and cost) was retrieved from the pharmaceutical re-
gional database. The local Hypertension Centre retrieved
number and typology of specialist consultations and pro-
cedures. Indirect costs were partly calculated from social
security system certificates, and partly estimated under
the hypothesis that each hospital stay and each specialist
visits imply a loss of working days.
RESULTS: In 1997, 45 patients generated a total cost of
Lit. 29.9 million, with an average cost per patient per
year of Lit. 664,282. Pharmaceutical care accounted for
45% of total cost, followed by hospital admissions
(34%), productivity losses (16.4%), and specialist visits
and procedures (4.3%). 
CONCLUSIONS: This preliminary analysis has demon-
strated the potential of such an instrument to evaluate the
cost of managing hypertension in a large area as the Pis-
toia province. Further research is needed on larger sam-
ples to identify patterns of resource use and to evaluate
the influence of illness severity on the total cost of this
disease.
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OBJECTIVE: To estimate the economic value of the 4F
catheter relative to the 6F in diagnostic coronary angiog-
raphy.
METHODS: A decision tree model was developed, based
on German practice patterns and costs. Expected total
costs of diagnostic coronary angiography using 4F and 6F
catheters in both the ambulatory and inpatient settings
were calculated and compared, together with measures of
procedure success. Costs include the costs of catheters,
contrast media, time in clinic, professional services, and
costs to treat complications. Measures of procedure suc-
cess, as observed in trials of 4F versus 6F, include fluoros-
copy, procedure, compression, and immobilization times;
complication rates; and catheter exchange rates. Complica-
tion rates are those observed in two large German observa-
tional studies. 
RESULTS: In the base-case scenario, the 4F catheter
saves an average of 22 DM per procedure, despite a
higher list price. These savings derive primarily from re-
duced need for contrast media. The 4F is associated with
fewer complications; however, because of the low overall
complication rate, the associated savings are minor.
Given a lower likelihood of bleeding complications, the
4F may enable more procedures to be performed in the
ambulatory setting. Assuming a modest increase in the
proportion of ambulatory procedures results in an addi-
tional savings of 10 DM per procedure.
CONCLUSION: Compared to the 6F catheter, the 4F is
estimated to save an average of 22 DM per diagnostic
coronary angiography because of a reduced need for con-
trast media and a lower complication rate. If the 4F cath-
eter enables more procedures to be performed on an out-
patient basis, the potential cost savings increase.
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Admission (%) Discharge (%)
Arterial BP 140/90 mmHg 24 ** 8
Smoking 39 ** 5
Cholesterol 250 mg/dl 20 ** 5
LDL cholesterol 100 mg/dl 87 ** 67
LDL/HDL cholesterol 2.5 86 ** 70
Triglycerides 200 mg/dl 22 * 15
Glucose 140 mg/dl 14 ns 11
BMI 30 kg/m2 18 * 15
* p  0.01, ** p  0.001, ns  not significant.
